Binimetinib
A targeted therapy that inhibits the MEK enzyme in the MAPK signaling pathway, which is often abnormally activated in certain cancers. It is used in combination with another targeted agent to treat melanoma and other tumors with specific genetic mutations. Side effects can include rash, visual disturbances, and elevated liver enzymes.
Молекулярная масса
441,2000 g/mol
LogP
3,10
TPSA
88,40 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
2D Структура
Cite this structure
Embed this structure
SMILES
Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(C(=O)NOCCO)cc21
InChI
InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
Molecular Formula
C17H15BrF2N4O3
HBD / HBA
3 / 7
Вращаемые Связи
6
Тяжёлые Атомы
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
A targeted therapy that inhibits the MEK enzyme in the MAPK signaling pathway, which is often abnormally activated in certain cancers. It is used in combination with another targeted agent to treat melanoma and other tumors with specific genetic mutations. Side effects can include rash, visual disturbances, and elevated liver enzymes.
Inhibits MEK1 and/or MEK2 kinases in the RAS/MAPK signaling pathway, blocking the transmission of growth signals that promote cancer cell proliferation and survival.
Yes, Binimetinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3187723. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10288191. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="binimetinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/binimetinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/binimetinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/binimetinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="binimetinib"></drugfyi-drug>